ARISTO has been consistently growing faster than the Indian Pharma Market. This makes us the 3rd largest company in the product segments where we have our presence (IQVIA JUNE 2023, covered market data).
Having grown consistently year over year, we have reached the league of top ten Indian owned pharma organisations by turnover (IQVIA JUNE 2023). We have achieved this distinction despite operating with only 5 marketing divisions to promote our product portfolio. On the prescription front, we are ranked 8th (SMSRC prescription audit MAT JAN - JULY 2023) which reflects the trust that the medical fraternity has in us.
ARISTO believes in building and nurturing brands to a leadership position in respective segments. The efforts in this direction have made ten brands feature in the coveted top 300 brands of the Indian Pharma Market.
Right since its inception, ARISTO has believed in introducing well differentiated formulations backed by its innovative R&D team. As a result, till date, ARISTO has the distinction of introducing over 21 formulations for the first time in India.